Cargando…

Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)

BACKGROUND: Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL‐17A, has been shown to have significant efficacy and a favourable safety profile in the treatment of moderate‐to‐severe psoriasis and psoriatic arthritis. OBJECTIVE: To assess the efficacy and safety of secuki...

Descripción completa

Detalles Bibliográficos
Autores principales: Bissonnette, R., Luger, T., Thaçi, D., Toth, D., Lacombe, A., Xia, S., Mazur, R., Patekar, M., Charef, P., Milutinovic, M., Leonardi, C., Mrowietz, U.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175198/
https://www.ncbi.nlm.nih.gov/pubmed/29444376
http://dx.doi.org/10.1111/jdv.14878
_version_ 1783361452954877952
author Bissonnette, R.
Luger, T.
Thaçi, D.
Toth, D.
Lacombe, A.
Xia, S.
Mazur, R.
Patekar, M.
Charef, P.
Milutinovic, M.
Leonardi, C.
Mrowietz, U.
author_facet Bissonnette, R.
Luger, T.
Thaçi, D.
Toth, D.
Lacombe, A.
Xia, S.
Mazur, R.
Patekar, M.
Charef, P.
Milutinovic, M.
Leonardi, C.
Mrowietz, U.
author_sort Bissonnette, R.
collection PubMed
description BACKGROUND: Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL‐17A, has been shown to have significant efficacy and a favourable safety profile in the treatment of moderate‐to‐severe psoriasis and psoriatic arthritis. OBJECTIVE: To assess the efficacy and safety of secukinumab through 5 years of treatment in moderate‐to‐severe psoriasis. METHODS: In the core SCULPTURE study, Psoriasis Area and Severity Index (PASI) 75 responders at Week 12 continued receiving subcutaneous secukinumab until Year 1. Thereafter, patients entered the extension phase and continued treatment as per the core trial. Treatment was double‐blinded until the end of Year 3 and open‐label from Year 4. Here, we focus on the 300 mg fixed‐interval (every 4 weeks) treatment, the recommended per label dose. Efficacy data are primarily reported as observed, but multiple imputation (MI) and last observation carried forward (LOCF) techniques were also undertaken as supportive analyses. RESULTS: At Year 1, 168 patients entered the extension study and at the end of Year 5, 126 patients completed 300 mg (every 4 weeks) treatment. PASI 75/90/100 responses at Year 1 (88.9%, 68.5% and 43.8%, respectively) were sustained to Year 5 (88.5%, 66.4% and 41%). PASI responses were consistent regardless of the analysis undertaken (as observed, MI, or LOCF). The average improvement in mean PASI was approximately 90% through 5 years compared with core study baseline. DLQI (dermatology life quality index) 0/1 response also sustained through 5 years (72.7% at Year 1 and 65.5% at Year 5). The safety profile of secukinumab remained favourable, with no cumulative or unexpected safety concerns identified. CONCLUSION: Secukinumab 300 mg treatment delivered high and sustained levels of skin clearance and improved quality of life through 5 years in patients with moderate‐to‐severe psoriasis. Favourable safety established in the secukinumab phase 2/3 programme was maintained through 5 years.
format Online
Article
Text
id pubmed-6175198
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-61751982018-10-15 Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (SCULPTURE Extension Study) Bissonnette, R. Luger, T. Thaçi, D. Toth, D. Lacombe, A. Xia, S. Mazur, R. Patekar, M. Charef, P. Milutinovic, M. Leonardi, C. Mrowietz, U. J Eur Acad Dermatol Venereol Psoriasis BACKGROUND: Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL‐17A, has been shown to have significant efficacy and a favourable safety profile in the treatment of moderate‐to‐severe psoriasis and psoriatic arthritis. OBJECTIVE: To assess the efficacy and safety of secukinumab through 5 years of treatment in moderate‐to‐severe psoriasis. METHODS: In the core SCULPTURE study, Psoriasis Area and Severity Index (PASI) 75 responders at Week 12 continued receiving subcutaneous secukinumab until Year 1. Thereafter, patients entered the extension phase and continued treatment as per the core trial. Treatment was double‐blinded until the end of Year 3 and open‐label from Year 4. Here, we focus on the 300 mg fixed‐interval (every 4 weeks) treatment, the recommended per label dose. Efficacy data are primarily reported as observed, but multiple imputation (MI) and last observation carried forward (LOCF) techniques were also undertaken as supportive analyses. RESULTS: At Year 1, 168 patients entered the extension study and at the end of Year 5, 126 patients completed 300 mg (every 4 weeks) treatment. PASI 75/90/100 responses at Year 1 (88.9%, 68.5% and 43.8%, respectively) were sustained to Year 5 (88.5%, 66.4% and 41%). PASI responses were consistent regardless of the analysis undertaken (as observed, MI, or LOCF). The average improvement in mean PASI was approximately 90% through 5 years compared with core study baseline. DLQI (dermatology life quality index) 0/1 response also sustained through 5 years (72.7% at Year 1 and 65.5% at Year 5). The safety profile of secukinumab remained favourable, with no cumulative or unexpected safety concerns identified. CONCLUSION: Secukinumab 300 mg treatment delivered high and sustained levels of skin clearance and improved quality of life through 5 years in patients with moderate‐to‐severe psoriasis. Favourable safety established in the secukinumab phase 2/3 programme was maintained through 5 years. John Wiley and Sons Inc. 2018-03-22 2018-09 /pmc/articles/PMC6175198/ /pubmed/29444376 http://dx.doi.org/10.1111/jdv.14878 Text en © 2018 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Psoriasis
Bissonnette, R.
Luger, T.
Thaçi, D.
Toth, D.
Lacombe, A.
Xia, S.
Mazur, R.
Patekar, M.
Charef, P.
Milutinovic, M.
Leonardi, C.
Mrowietz, U.
Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)
title Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)
title_full Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)
title_fullStr Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)
title_full_unstemmed Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)
title_short Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)
title_sort secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (sculpture extension study)
topic Psoriasis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175198/
https://www.ncbi.nlm.nih.gov/pubmed/29444376
http://dx.doi.org/10.1111/jdv.14878
work_keys_str_mv AT bissonnetter secukinumabdemonstrateshighsustainedefficacyandafavourablesafetyprofileinpatientswithmoderatetoseverepsoriasisthrough5yearsoftreatmentsculptureextensionstudy
AT lugert secukinumabdemonstrateshighsustainedefficacyandafavourablesafetyprofileinpatientswithmoderatetoseverepsoriasisthrough5yearsoftreatmentsculptureextensionstudy
AT thacid secukinumabdemonstrateshighsustainedefficacyandafavourablesafetyprofileinpatientswithmoderatetoseverepsoriasisthrough5yearsoftreatmentsculptureextensionstudy
AT tothd secukinumabdemonstrateshighsustainedefficacyandafavourablesafetyprofileinpatientswithmoderatetoseverepsoriasisthrough5yearsoftreatmentsculptureextensionstudy
AT lacombea secukinumabdemonstrateshighsustainedefficacyandafavourablesafetyprofileinpatientswithmoderatetoseverepsoriasisthrough5yearsoftreatmentsculptureextensionstudy
AT xias secukinumabdemonstrateshighsustainedefficacyandafavourablesafetyprofileinpatientswithmoderatetoseverepsoriasisthrough5yearsoftreatmentsculptureextensionstudy
AT mazurr secukinumabdemonstrateshighsustainedefficacyandafavourablesafetyprofileinpatientswithmoderatetoseverepsoriasisthrough5yearsoftreatmentsculptureextensionstudy
AT patekarm secukinumabdemonstrateshighsustainedefficacyandafavourablesafetyprofileinpatientswithmoderatetoseverepsoriasisthrough5yearsoftreatmentsculptureextensionstudy
AT charefp secukinumabdemonstrateshighsustainedefficacyandafavourablesafetyprofileinpatientswithmoderatetoseverepsoriasisthrough5yearsoftreatmentsculptureextensionstudy
AT milutinovicm secukinumabdemonstrateshighsustainedefficacyandafavourablesafetyprofileinpatientswithmoderatetoseverepsoriasisthrough5yearsoftreatmentsculptureextensionstudy
AT leonardic secukinumabdemonstrateshighsustainedefficacyandafavourablesafetyprofileinpatientswithmoderatetoseverepsoriasisthrough5yearsoftreatmentsculptureextensionstudy
AT mrowietzu secukinumabdemonstrateshighsustainedefficacyandafavourablesafetyprofileinpatientswithmoderatetoseverepsoriasisthrough5yearsoftreatmentsculptureextensionstudy